Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 20 versus ADZENYS ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 20 versus ADZENYS ER.
ADDERALL 20 vs ADZENYS ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
None Documented
None Documented
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Category C
Category C
CNS Stimulant
CNS Stimulant